PLUS THERAPEUTICS director gets new equity awards
van Es-Johansson An reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
van Es-Johansson An reported acquisition or exercise transactions in this Form 4 filing.
PLUS THERAPEUTICS director An van Es-Johansson received new equity awards. On May 14, 2026, the director was granted options to buy 3,686 shares of common stock at $5.76 per share, expiring on May 14, 2036, vesting monthly over 12 months or fully at the 2027 Annual Stockholder Meeting. The director also received 3,686 restricted stock units, each representing one share, vesting in four equal quarterly installments starting July 1, 2026.
Insider Trade Summary
Grant/Award: 7,372 shares
Grant/Award
2 txns
Insider
van Es-Johansson An
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 3,686 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 3,686 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 3,686 contracts (Direct);
Stock Option (Right to Buy) — 3,686 contracts (Direct)
Footnotes (2)
- F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
- F2. The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.
Key Figures
Stock options granted: 3,686 options
Option exercise price: $5.76 per share
Option expiration: May 14, 2036
+3 more
6 metrics
Stock options granted
3,686 options
Grant to director on May 14, 2026
Option exercise price
$5.76 per share
Stock Option (Right to Buy) for common stock
Option expiration
May 14, 2036
Expiration date of granted stock options
RSUs granted
3,686 RSUs
Restricted Stock Units tied to common stock
RSU vesting start
July 1, 2026
First 1/4 RSU vesting date
Option vesting period
12 months
Monthly vesting or full vesting by 2027 Annual Meeting
Key Terms
Restricted Stock Units, Stock Option (Right to Buy), vest ratably, Annual Stockholder Meeting
4 terms
Restricted Stock Units financial
"The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with an exercise price of 5.7600"
vest ratably financial
"The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments"
Annual Stockholder Meeting financial
"options vest in full on the Issuer's 2027 Annual Stockholder Meeting"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did PLUS THERAPEUTICS (PSTV) director An van Es-Johansson receive in this Form 4?
The director received equity-based compensation: 3,686 stock options and 3,686 restricted stock units. Both awards relate to PLUS THERAPEUTICS common stock and are structured to vest over time, encouraging continued board service and long-term alignment with shareholders.
What are the key terms of the PLUS THERAPEUTICS (PSTV) stock options granted?
The options cover 3,686 shares of common stock at an exercise price of $5.76 per share. They vest in substantially equal monthly increments over 12 months and expire on May 14, 2036, or earlier under standard plan conditions tied to service.
How do the restricted stock units in this PLUS THERAPEUTICS (PSTV) filing vest?
Each of the 3,686 RSUs represents a right to receive one share of common stock. The RSUs vest ratably in four equal one-quarter increments, beginning July 1, 2026, with additional quarterly vesting thereafter, subject to the director’s continued service.
Is the Form 4 transaction for PLUS THERAPEUTICS (PSTV) a stock purchase or a grant?
The Form 4 reflects equity grants, not an open-market stock purchase. It reports the award of stock options and restricted stock units as director compensation, with no cash paid by the insider at grant and vesting schedules defined in the award terms.
Does the PLUS THERAPEUTICS (PSTV) director need to pay anything for the RSUs and options?
The RSUs do not require payment when they vest; they convert into shares. The stock options have an exercise price of $5.76 per share, which must be paid if the director chooses to exercise them before their May 14, 2036 expiration.
What service condition is tied to the PLUS THERAPEUTICS (PSTV) option vesting?
Option vesting depends on continued service as a director and the 2027 Annual Stockholder Meeting. The options vest monthly over 12 months, but will vest in full by the 2027 annual meeting if the director remains in service through each applicable vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
